ALB 109564(a)

Drug Profile

ALB 109564(a)

Alternative Names: 12'-methylthiovinblastine dihydrochloride; ALB109564(a)

Latest Information Update: 09 Sep 2016

Price : $50

At a glance

  • Originator AMRI
  • Class Antineoplastics; Vinca alkaloids
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 07 Sep 2016 ALB 109564 (a) is still in phase I trials for Solid tumours in USA (Bessor Pharma pipeline, September 2016)
  • 11 Feb 2013 ALB 109564(a) licensed to Chai Therapeutics worldwide
  • 03 Apr 2012 Phase-I clinical trials in Solid tumours in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top